Kiora Pharmaceuticals, Inc. - Common Stock (KPRX)

From $30 million Solana, Bitcoin staking and rare cancer breakthroughs to critical minerals exploration and transformative mergers, these companies—are reshaping the landscape of blockchain, biotech, digital health, and resource innovation. Investors should closely monitor these stocks as catalysts unfold across global markets.

Phoenix, Arizona and New York, New York--(Newsfile Corp. - September 30, 2024) - Lytham...

Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and...

Kiora Pharmaceuticals Inc. (NASDAQ:KPRX) traded today at a new 52-week high of $6.65. Approximately 147,000 shares have changed hands today, as compared to an average 30-day volume of 19 million shares.

Phase 2 trial for KIO-301 for the treatment of retinitis pigmentosa, in partnership with Théa Open Innovation, expected to be...

Topline Phase I/II First-in-Human Results Presented at AAO 2023Significant improvement in visual field, in concordance with trended improvements in visual...

Encinitas, California--(Newsfile Corp. - August 22, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), a clinical-stage biotechnology company developing novel therapies...

Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

Dallas, Texas--(Newsfile Corp. - December 14, 2022) - Stonegate Healthcare has published a new...

Dallas, Texas--(Newsfile Corp. - September 28, 2022) - Stonegate Capital Partners will host a...

San Diego, CA -- (SBWIRE) -- 02/15/2022 -- An investigation was announced for investors of Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc. (NASDAQ:KPRX, formerly NASDAQ:EYEG) shares over potential securities laws violations by Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc.

San Diego, CA -- (SBWIRE) -- 12/15/2021 -- An investigation was announced for investors of Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc. (NASDAQ:KPRX, formerly NASDAQ:EYEG) shares over potential securities laws violations by Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc.

San Diego, CA -- (SBWIRE) -- 12/01/2021 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Kiora Pharmaceuticals, Inc f.k.a. EyeGate Pharmaceuticals, Inc. .